{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-009651","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.591769+00:00","generated_at":"2026-06-25T18:31:48.985492+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Bolt Biotherapeutics Q1 2022: Cash $246.8M; BDC-1001 data on track for H2 2022","bullets":["Cash, cash equivalents and marketable securities $246.8M at March 31, 2022; expected to fund operations into 2024.","Collaboration revenue $0.8M from Genmab and Innovent partnerships; R&D expenses $18.4M vs $14.1M prior year.","Loss from operations $23.9M vs $18.4M in Q1 2021, reflecting increased clinical and IND-enabling activities.","Lead ISAC BDC-1001 monotherapy and OPDIVO combo dose escalation on track; data readout expected H2 2022.","IND-enabling activities for CEA-targeted BDC-2034 and Dectin-2 agonist BDC-3042 progressing; BDC-3042 clinical start planned 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-009651","json":"https://secwatch.observer/filing/0000950170-22-009651.json","markdown":"https://secwatch.observer/filing/0000950170-22-009651.md","text":"https://secwatch.observer/filing/0000950170-22-009651.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000095017022009651/0000950170-22-009651-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000095017022009651/bolt-20220512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T18:31:48.985492+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}